Bone marrow stromal cells reduce axonal loss in experimental autoimmune encephalomyelitis mice.
We investigated the ability of human bone marrow stromal cell (hBMSC) treatment to reduce axonal loss in experimental autoimmune encephalomyelitis (EAE) mice. EAE was induced in SJL/J mice by injection with proteolipid protein (PLP). Mice were injected intravenously with hBMSCs or PBS on the day of clinical onset, and neurological function was measured daily (score 0-5) until 45 weeks after onset. Mice were sacrificed at week 1, 10, 20, 34, and 45 after clinical onset. Bielshowsky silver was used to identify axons. Immunohistochemistry was performed to measure the expression of nerve growth factor (NGF) and MAB1281, a marker of hBMSCs. hBMSC treatment significantly reduced the mortality, the disease severity, and the number of relapses in EAE mice compared with PBS treatment. Axonal density and NGF(+) cells in the EAE brain were significantly increased in the hBMSC group compared with the PBS group at 1, 10, 20, 34, and 45 weeks. Disease severity was significantly correlated with decreased axonal density and decreased NGF, and increased axonal density was significantly correlated with reduced loss of NGF expression after hBMSC treatment. Most of the NGF(+) cells are brain parenchymal cells. Under 5% of MAB1281(+) cells colocalized with NG2(+), a marker of oligodendrocyte progenitor cells. Nearly 10% of MAB1281(+) cells colocalized with GFAP, a marker of astrocytes, and MAP-2, a marker of neurons. Our findings indicate that hBMSCs improve functional recovery and may provide a potential therapy aimed at axonal protection in EAE mice, in which NGF may play a vital role.
Zhang
Jing
J
Department of Neurology, Henry Ford Health Sciences Center, Detroit, Michigan 48202, USA.
Li
Yi
Y
Lu
Mei
M
Cui
Yisheng
Y
Chen
Jieli
J
Noffsinger
Lori
L
Elias
Stanton B
SB
Chopp
Michael
M
D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism; D001369:Axons / Q000378:metabolism / Q000648:ultrastructure; D015415:Biomarkers / Q000378:metabolism; D016026:Bone Marrow Transplantation / Q000379:methods*; D001921:Brain / Q000166:cytology / Q000378:metabolism; D002454:Cell Differentiation / Q000502:physiology; D002478:Cells, Cultured; D004195:Disease Models, Animal; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000276:immunology* / Q000503:physiopathology / Q000628:therapy*; D005260:Female; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D006085:Graft Survival / Q000502:physiology; D006801:Humans; D007275:Injections, Intravenous; D051379:Mice; D008869:Microtubule-Associated Proteins / Q000378:metabolism; D020932:Nerve Growth Factor / Q000378:metabolism; D017154:Stromal Cells / Q000637:transplantation*; D014183:Transplantation, Heterologous / Q000379:methods; D016896:Treatment Outcome; D014855:Wallerian Degeneration / Q000276:immunology* / Q000503:physiopathology / Q000628:therapy*
D000911:Antibodies, Monoclonal; D015415:Biomarkers; D005904:Glial Fibrillary Acidic Protein; D008869:Microtubule-Associated Proteins; C079240:Mtap2 protein, mouse; D020932:Nerve Growth Factor